Cardiovascular effects of selective serotonin reuptake inhibitor antidepressants;A szelektív szerotonin-visszavételt gátló antidepresszánsok cardiovascularis hatásai

Orvosi Hetilap

Volumn 145, Issue 8, 2004, Pages 425-431

  Pacher, Pál ^a,b   Kecskeméti, Valéria ^a,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NONE   (Hungary)

Author keywords

Antidepressant drugs; Cardiac and smooth muscles; Citalopram; Fluoxetine; Voltage gated ion channels

Indexed keywords

CALCIUM CHANNEL; CITALOPRAM; FLUOXETINE; ION CHANNEL; POTASSIUM CHANNEL; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; HEART MUSCLE; HUMAN; INTESTINE MUSCLE; ION CURRENT; REVIEW; SMOOTH MUSCLE RELAXATION; VASCULAR SMOOTH MUSCLE; CARDIOVASCULAR SYSTEM; CHANNEL GATING; HEART;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CALCIUM CHANNELS; CARDIOVASCULAR SYSTEM; CITALOPRAM; FLUOXETINE; HEART; HUMANS; ION CHANNEL GATING; ION CHANNELS; MUSCLE, SMOOTH, VASCULAR; POTASSIUM CHANNELS; SEROTONIN UPTAKE INHIBITORS; SODIUM CHANNELS;

EID: 2342521981     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Ariyo, A.A., Haan, M., Tangen, C. M. és mtsai: for the Cardiovascular Health Study Collaborative research Group. Depressive symptoms and risk of coronary heart disease and mortality in elderly Americans. Circulation, 2000, 102, 1773-1779.
2. Baker, B., Dorian, P., Sandor, P. és mtsai: Electrocardiographic effects of fluoxetine and doxepin on patients with major depressive disorder. J. Clin. Psychopharmacol., 1997, 17, 15-21.
3. Barber, M., Starmer, C. F., Grant, A. O.: Blockade of cardiac sodium channels by amitriptyline and diphenylhidantoin. Evidence for two use-dependent binding sites. Circ. Res., 1991, 69, 677-696.
4. Barbey, J. T., Roose, S. P.: SSRI safety in overdose. J. Clin. Psychiatry, 1998, 59, 42-48.
5. Bigger, J. T., Giardina, E. G., Perel, J. M. és mtsai: Cardiac antiarrhythmic effect of imipramine hydrochloride. N. Engl. J. Med., 1977, 296, 206-208.
6. Bou-Abboud, E., Nattel S.: Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes. Cardiovasc. Res., 1998, 38, 395-404.
7. Buff, D. D., Brenner, R., Kirtane, S. S. és mtsai: Dysrhythmia associated with fluoxetine treatment in elderly patients with cardiac disease. J. Clin. Psychiatry, 1991, 52, 174-176.
8. Choi, B. H., Choi, J. S., Yoon, S. H. és mtsai: Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology, 2001, 41, 443-53.
9. Choi, J. S., Hahn, S. J., Rhie, D. J. és mtsai: Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J. Pharmacol. Exp. Ther., 1999, 291, 1-6.
10. Cooper, L.G.: The safety of fluoxetine: an update. Br. J. Psychiatry, 1988, 153, 77-86.
11. Dalfen, A. K., Stewart, D. E.: Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors. Can. J. Psychiatry, 2001, 46, 258-263.
12. Davidson, E. T.: Amitriptyline induced Torsades de Pointes. Successful therapy with atrial pacing. J. Electrocardiol., 1985, 18, 299-301.
13. De Ponti, F., Poluzzi, E., Montanaro, N.: Organising evidence on QT prolongation and occurrence of Torsade de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Pharmacol., 2001, 57, 185-209.
14. Deák, F., Lasztóczi, B., Packer, P. és mtsai: Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacol., 2000, 39, 1029-1036.
15. Delpon, E., Tamargo, J., Sanchez-Chapula J.: Effects of imipramine on the transient outward current in rabbit atrial single cells. Brit. J. Pharmacol., 1992, 106, 464-469.
16. Drake, W. M., Gordon, G. D.: Heart block in a patient on propranolol and fluoxetine. Lancet, 1994, 343, 425-426.
17. Enemark, B.: The importance of ECG monitoring in antidepressant treatment. Nord. J. Psychiatry, 1993, 47, 57-65.
18. Erfuth, A., Loew, M., Dobmeier, P. és mtsai: EKG-Veranderungen nach Paroxetin. Drei Fallberichte Nervenarzt, 1998, 69, 629-631.
19. Favale, E., Rubino, V., Mainardi, P. és mtsai: Anticonvulsant effect of fluoxetine in humans. Neurology, 1995, 45, 1926-1927.
20. Feerketich, A. K., Schwartzbaum, J. A., Frod, D. J. és mtsai: for the National Health and Nutrition Examination Survey. Depression as an antescendent to heart disease among women and men in the NHANES I study. Arch. Intern. Med., 2000, 160, 1261-1268.
21. Friedman, E. H.: Fluoxetine-induced bradycardia. J. Clin. Psychiatry, 1991, 52, 174-176.
22. Glassman, A.H.: Cardiovascular effects of tricyclic antidepressants. Annu. Rev. Med., 1984, 35, 503-511.
23. Glassman, A. H., OConnor, C. M., Califf, R. M. és mtsai: Sertaline treatment of major depression in patients with acute MI or unstable angina. JAMA, 2002, 288, 701-709.
24. Habuchi, Y., Furukawa T., Tanaka, H. és mtsai: Block of Na+ channels by imipramine in guinea-pig cardiac ventricular cells. J. Pharmacol. Exp. Ther., 1991, 256, 1072-1081.
25. Hahn, S. J., Choi, J. S., Rhie, D. J. és mtsai: Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells. Eur. J. Pharmacol., 1999, 367, 113-118.
26. Hamplova-Peichlova, J., Krusek, J., Paclt, I. és mtsai: Citalopram inhibits L-type calcium channel current in rat cardiomycytes in culture. Physiol. Res. 2002, 51, 317-321.
27. Henry, J. A.: Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Safety, 1997, 16, 374-390.
28. Jo, S. H., Youm, J. B., Lee, C. O. és mtsai: Blockade of the HERG human cardiac K+ channel by the antidepressant drug amitriptyline. Brit. J. Pharmacol., 2000, 129, 1474-1480.
29. Kecskeméti, V., Pacher P.: Fluoxetine: an SSRI and effective ion(calcium)-channels antagonist. Neuropsychopharmacol. Hung., 2002, 4, 197-206.
30. Khalifa, M., Daleau P., Turgeon J.: Mechanism of sodium channel block by venlafaxine in guinea-pig ventricular myocytes. J. Pharmacol. Exp. Ther., 1999, 291, 280-284.
31. Kroenke, K., West, S. I., Swindle, R. és mtsai: Similar effectiveness if paroxetine, fluoxetine and sertaline in primary care. Randomized trial. JAMA, 2001, 256, 2947-2955.
32. Leonard, B. E.: Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs, 1992, 43, 3-10.
33. Lesperance, F., Frasure-Smith, N., Juneau, M. és mtsai: Depression and 1 -year prognosis in unstable angina Arch. Int. Med., 2000, 160, 1354-1360.
34. Livshits, A.T.L. Danenberg, H.D.: Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry, 1997, 30, 274-275.
35. Magyar, J., Rusznák, Z., Harasztos, C. S. és mtsai: Differential effects of R(-) and S(+) enantiomers of fluoxetine in mammalian neural and cardiac tissues. Int. J. Mol. Med., 2003, 11, 535-542.
36. Meier, C. R., Schlienger, R. G., Jick, H.: Use of serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br. J. Clin. Pharmacol., 2001, 52, 79-184.
37. Ostrom, M., Eriksson, A., Thorson, J. és mtsai: Fatal overdose with citalopram. Lancet, 1996, 348, 339-340.
38. Pacher, P., Ungvari, Z.: Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med. Hypothesis, 2001, 57, 469-471.
39. Packer, P., Bagi, Zs., Lako-Futo, Z. és mtsai: Cardiac electrophysiological effects of citalopram in guinea pig papillary muscle. Comparison with clomipramine. Gen. Pharmacol., 2000, 34, 17-23.
40. Pacher, P., Magyar, J., Szigligeti, P. és mtsai: Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedeberg's Arch. Pharmacol., 2000, 361, 67-73.
41. 2+ sensitivity. Br. J. Pharmacol., 1999, 127, 740-746.
42. Packer, P., Ungvari, Z., Kecskemeti, V. és mtsai: Serotonin reuptake inhibitors fluoxetine and citalopram relax inteastinal smooth muscle. Can. J. Physiol. Pharmacol., 2001, 79, 580-584.
43. Pacher, P., Ungvári, Z., Nánási, P. P. és mtsai: Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr. Med. Chem., 1999, 6, 469-480.
44. Park, K. S., Kong, I. K., Park, K. C. és mtsai: Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med. J., 1999, 40, 144-151.
45. Pato, M. T., Murphy, D. L., Devane, C. L.: Sustained plasma concentrations of fluoxetine/or norfluoxetine four or eight weeks after fluoxetine discontinuation. J. Clin. Psychopharmacol., 1991, 11, 224-225.
46. Pentel, P. R., Benovitz, N. L.: Tricyclic antidepressants poisoning. Management of arrhythmias. Med. Toxicol., 1986, 1, 101-021.
47. Philips, S., Brent, J., Kulig, K. és mtsai: Fluoxetine versus tricyclic antidepressants: a prospective multicenter study of antidepressant drug overdoses, the Antidepressant Study Group. J. Emerg. Med., 1997, 15, 439-445.
48. Ravina, T., Suarez, M. L. R., Mendez-Castrilon, J.: Fluoxetine-induced QTU interval prolongation, T wave alternans and syncope. Int. J. Cardiol.,1998, 65, 311-313.
49. Richelson, E.: Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin. Proc., 1997, 72, 835-847.
50. Roose, S. P., Laghrissi-Thode, F., Kennedy, J. S. és mtsai: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA, 1998, 279, 287-291.
51. Roose, S. P., Spatz, E.: Treatment of depression in patients with heart disease. J. Clin. Psychiatry, 1999, 60 (Suppl 20), 34-37.
52. Sauer, W. H., Berlin, J. A., Kimmel, S. E.: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation, 2001, 104, 1894-1898.
53. Teschemacher, A. G., Seward, E. P., Hancox, J. C. és mtsa: Inhibition of the current of the heterologously expressed HERG potassium channels by imipramine and amitriptyline. Brit. J. Pharmacol., 1999, 128, 479-485.
54. Thomas, D., Gut, B., Wendt-Nordahl, G. és mtsai: The antidepressant drug fluoxetine is an inhibitor of human either-a-go-go-related gene (HERG) potassium channels. J. Pharmacol. Exp. Ther., 2002, 300, 543-548.
55. Ungvari, Z., Pacher, P., Kecskemeti, V. és mtsai: Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine and voltage-dependent Ca2+ channel opener. Stroke, 1999, 30, 1949-1954.
56. Witchel, H. J., Hancox, J. C. Nutt, D. J.: Psychotropic drugs, cardiac arrhythmia, and sudden death. J. Clin. Psychopharmacol., 2003, 23, 58-77.
57. Witchel, H. J., Pabbathi, V. K., Hofmann, G. és mtsai: Inhibitory action of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Letters, 2002, 512, 59-66.